Medlab Clinical (ASX:MDC) - Cours de l'action, nouvelles et analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

MDC Aperçu des actions

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.

A propos de l'entreprise

MDC analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	2/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Revenue is forecast to grow 41.74% per year

Trading at good value compared to peers and industry

Analyse des risques

Shares are highly illiquid

Earnings are forecast to decline by an average of 44.7% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (A$15M)

+ 1 plus de risques

Medlab Clinical Limited Concurrents

Immuron

ASX:IMC

AU$22.8m

Cynata Therapeutics

ASX:CYP

AU$35.2m

Noxopharm

ASX:NOX

AU$28.1m

AdAlta

ASX:1AD

AU$12.5m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Medlab Clinical
Historique des cours de bourse
Prix actuel de l'action	AU$6.60
Plus haut sur 52 semaines	AU$14.94
Plus bas sur 52 semaines	AU$6.45
Bêta	1.1
1Variation sur 1 mois	0%
Variation sur 3 mois	-4.21%
Variation sur 1 an	-43.59%
3Variation sur 3 ans	-79.05%
Variation sur 5 ans	-91.85%
Évolution depuis l'introduction en bourse	-78.00%

Nouvelles et mises à jour récentes

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Rendement pour les actionnaires

	MDC	AU Biotechs	AU Marché
7D	0%	-0.5%	0.7%
1Y	-43.6%	16.0%	10.5%

Rendement vs Industrie: MDC underperformed the Australian Biotechs industry which returned 11.4% over the past year.

Rendement vs marché: MDC underperformed the Australian Market which returned -1.5% over the past year.

Volatilité des prix

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement	n/a
Biotechs Industry Average Movement	12.1%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.5%

Cours de l'action stable: MDC has not had significant price volatility in the past 3 months.

Volatilité au fil du temps: Insufficient data to determine MDC's volatility change over the past year.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2012	n/a	Sean Hall	www.medlab.co

Medlab Clinical Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de Medlab Clinical se comparent-ils à sa capitalisation boursière ?
MDC statistiques fondamentales
Capitalisation boursière	AU$15.07m
Bénéfices(TTM)	-AU$8.32m
Recettes(TTM)	AU$1.54m

9.8x

Ratio P/S

-1.8x

Ratio P/E

Le site MDC est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
MDC compte de résultat (TTM)
Recettes	AU$1.54m
Coût des recettes	AU$336.29k
Marge brute	AU$1.20m
Autres dépenses	AU$9.52m
Les revenus	-AU$8.32m

Derniers bénéfices déclarés

Jun 30, 2022

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-3.64
Marge brute	78.11%
Marge bénéficiaire nette	-541.67%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de MDC?

Voir les performances historiques et les comparaisons

This company listing is no longer active

MDC Aperçu des actions

Récompenses

Analyse des risques

Medlab Clinical Limited Concurrents

ASX:IMC

AU$22.8m

ASX:CYP

AU$35.2m

ASX:NOX

AU$28.1m

ASX:1AD

AU$12.5m

Historique des prix et performances

Nouvelles et mises à jour récentes

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding